Cartesian Therapeutics, Inc.
Income Statement
| Line Item | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|
| Revenue | $903.0K | $207.0K | $8.1M | $6.0M | $3.0M |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Gross Margin | — | — | — | — | — |
| Operating Expenses | |||||
| Research & Development | $47.7M | $45.2M | $29.7M | $23.0M | $10.5M |
| SG&A Expense | $18.2M | $18.8M | $13.1M | $8.3M | $8.0M |
| Operating Income | $-65.0M | $-63.8M | $-34.7M | $-25.3M | $-15.4M |
| Operating Margin | -7,200.7% | -30,813.5% | -428.9% | -421.0% | -506.5% |
| Interest Expense | $1.5M | $1.2M | $1.3M | $948.0K | $552.0K |
| Pretax Income | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — |
| Net Income | $-65.3M | $-65.3M | $-36.2M | $-25.2M | $-12.9M |
| Net Margin | -7,235.4% | -31,556.0% | -448.0% | -418.8% | -423.7% |
| EPS (Basic) | $-0.49 | $-0.53 | $-0.65 | $-2.52 | $-1.31 |
| EPS (Diluted) | $-0.49 | $-0.53 | $-0.65 | $-2.52 | $-1.31 |
| Shares Outstanding (Basic) | 134.8M | 134.1M | 110.6M | 13.0M | — |
| Shares Outstanding (Diluted) | 134.8M | 134.1M | 110.6M | 13.0M | — |
| Dividends Per Share | — | — | — | — | — |